Twittenhoff W D, Brittinger W D, Deckert D W, Belz G G, Schubert I
Arzneimittelforschung. 1978;28(3a):562-5.
26 patients with impaired renal function and 7 healthy subjects received an oral dose of 0.5 mg 14-Hydroxy-3-beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift) per day for 2 weeks. Plasma levels of meproscillarin were measured during and after this period by means of the 86Rb-erythrocyte method. No statistically significant differences were found between the 2 groups. The results are consistent with extrarenal elimination of the substance. Contrary to digoxin, e.g., dose reduction is unnecessary in chronic renal failure. Mild gastrointestinal symtpoms were the only side effects seen in 6 patients.
26例肾功能受损患者和7名健康受试者每日口服0.5毫克14-羟基-3-β-[(4-O-甲基-α-L-鼠李糖基)氧基]-14β-蟾蜍-4,20,22-三烯内酯（甲丙西拉林，克利夫特），持续2周。在此期间及之后，通过86Rb红细胞法测定甲丙西拉林的血浆水平。两组之间未发现统计学上的显著差异。结果与该物质的肾外消除一致。与地高辛相反，例如，慢性肾功能衰竭时无需减少剂量。6例患者仅出现轻微胃肠道症状。
